ReviewNutrients2021
Myricetin as a Promising Molecule for the Treatment of Post-Ischemic Brain Neurodegeneration.
Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Anti-Inflammatory Effects of Polyphenols in Brain Microvascular Endothelial Cells Stimulated with TNF-α.International journal of molecular sciences · 2026Article
- Aqueous extract of Acer truncatum leaves retards Drosophila melanogaster senescence by regulating amino acid metabolism and gut microbiota.Scientific reports · 2025Article
- Targeting the NLRP3 by Natural Compounds: Therapeutic Strategies to Mitigate Doxorubicin-Induced Cardiotoxicity.Cell biochemistry and biophysics · 2025Review
- Magnetic molecularly imprinted polymers for efficient solid-phase extraction and HPLC analysis of myricetin in pomegranate pomace.RSC advances · 2025Article
- Plant-Based Inhibitors of Protein Aggregation.Biomolecules · 2025Review
- The Potential of Selected Plants and Their Biologically Active Molecules in the Treatment of Depression and Anxiety Disorders.International journal of molecular sciences · 2025Review
- Natural products for intervertebral disc degeneration: mechanistic insights and therapeutic potentials.Frontiers in pharmacology · 2025Review
- Study on the Alleviating Effect and Potential Mechanism of Ethanolic Extract ofInternational journal of molecular sciences · 2023Article
- Dietary Polyphenols Decrease Chemokine Release by Human Primary Astrocytes Responding to Pro-Inflammatory Cytokines.Pharmaceutics · 2023Article
- Apitherapy in Post-Ischemic Brain Neurodegeneration of Alzheimer's Disease Proteinopathy: Focus on Honey and Its Flavonoids and Phenolic Acids.Molecules (Basel, Switzerland) · 2023Review
- Exploring the interaction of myricetin with human alpha-2-macroglobulin: biophysical and in-silico analysis.Journal of biological physics · 2023Article
- Honey and Alzheimer's Disease-Current Understanding and Future Prospects.Antioxidants (Basel, Switzerland) · 2023Review
- A Review on Polyphenols inNutrients · 2023Review
- The Effect of Selected Flavonoids and Lipoic Acid on Natural and Model Cell Membranes: Langmuir and Microelectrophoretic Methods.Molecules (Basel, Switzerland) · 2023Article
- Myricetin attenuates hypoxic-ischemic brain damage in neonatal ratsFrontiers in pharmacology · 2023Article
- Recent studies on myricetin and its biological and pharmacological activities.EXCLI journal · 2023Article
- Myricetin: targeting signaling networks in cancer and its implication in chemotherapy.Cancer cell international · 2022Review
- AMN Congress 2022 - Report of the panel on the effective treatment solutions for post-TBI cognitive problems.Journal of medicine and life · 2022Article
- Bioactive Natural Compounds for Therapeutic and Nutraceutical Applications in Neurodegeneration.Nutrients · 2022Article
- Covid 19: Diet Composition and Health.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The available drug therapy for post-ischemic neurodegeneration of the brain is symptomatic. This review provides an evaluation of possible dietary therapy for post-ischemic neurodegeneration with myricetin. The purpose of this review was to provide a comprehensive overview of what scientists have done regarding the benefits of myricetin in post-ischemic neurodegeneration. The data in this article contribute to a better understanding of the potential benefits of myricetin in the treatment of post-ischemic brain neurodegeneration, and inform physicians, scientists and patients, as well as their caregivers, about treatment options. Due to the pleiotropic properties of myricetin, including anti-amyloid, anti-phosphorylation of tau protein, anti-inflammatory, anti-oxidant and autophagous, as well as increasing acetylcholine, myricetin is a promising candidate for treatment after ischemia brain neurodegeneration with full-blown dementia. In this way, it may gain interest as a potential substance for the prophylaxis of the development of post-ischemic brain neurodegeneration. It is a safe substance, commercially available, inexpensive and registered as a pro-health product in the US and Europe. Taken together, the evidence available in the review on the therapeutic potential of myricetin provides helpful insight into the potential clinical utility of myricetin in treating neurodegenerative disorders with full-blown dementia. Therefore, myricetin may be a promising complementary agent in the future against the development of post-ischemic brain neurodegeneration. Indeed, there is a scientific rationale for the use of myricetin in the prevention and treatment of brain neurodegeneration caused by ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.